I agree that this site is using cookies. You can find further informations here.
X
Hege, Kristen
53  results:
Search for persons X
?
1

Idecabtagene vicleucel for relapsed and refractory multiple..:

Lin, Yi ; Raje, Noopur S. ; Berdeja, Jesús G....
Nature Medicine.  29 (2023)  9 - p. 2286-2294 , 2023
Link: https://doi.org/10.1038/..
 
?
2

Characterizing the exposure–response relationship of idecab..:

Connarn, Jamie N. ; Witjes, Han ; van Zutphen‐van Geffen, Marielle...
CPT: Pharmacometrics & Systems Pharmacology.  12 (2023)  11 - p. 1687-1697 , 2023
Link: https://doi.org/10.1002/..
 
?
3

S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR C..:

Bal, Susan ; Berdeja, Jesus ; Htut, Myo...
HemaSphere.  7 (2023)  S3 - p. e9863287 , 2023
Link: https://doi.org/10.1097/..
 
?
4

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in ..:

Zeidan, Amer M. ; DeAngelo, Daniel J. ; Palmer, Jeanne...
Annals of Hematology.  101 (2022)  3 - p. 557-569 , 2022
Link: https://doi.org/10.1007/..
 
?
5

Phase Ib study of combinations of avadomide (CC‐122), CC‐22..:

Ribrag, Vincent ; Chavez, Julio C. ; Boccomini, Carola...
eJHaem.  3 (2022)  1 - p. 139-153 , 2022
Link: https://doi.org/10.1002/..
 
?
6

Patient experience before and after treatment with idecabta..:

Shah, Nina ; Delforge, Michel ; San-Miguel, Jesus...
Leukemia Research.  120 (2022)  - p. 106921 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Matching adjusted indirect comparisons of efficacy outcomes..:

Rodriguez-Otero, Paula ; Ayers, Dieter ; Cope, Shannon...
Leukemia & Lymphoma.  62 (2021)  10 - p. 2482-2491 , 2021
Link: https://doi.org/10.1080/..
 
?
8

Context matters in CAR T cell tonic signaling:

Hege, Kristen
Nature Medicine.  27 (2021)  5 - p. 763-764 , 2021
Link: https://doi.org/10.1038/..
 
?
9

Biallelic loss of BCMA as a resistance mechanism to CAR T c..:

Samur, Mehmet Kemal ; Fulciniti, Mariateresa ; Aktas Samur, Anil...
Nature Communications.  12 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
10

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-d..:

Jr, Larry D. Anderson, ; Shah, Nina ; Jagannath, Sundar...
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S17-S18 , 2021
Link: https://doi.org/10.1016/..
 
?
11

Homozygous BCMA gene deletion in response to anti-BCMA CAR ..:

Da Vià, Matteo C. ; Dietrich, Oliver ; Truger, Marietta...
Nature Medicine.  27 (2021)  4 - p. 616-619 , 2021
Link: https://doi.org/10.1038/..
 
?
12

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How ..:

Kim, Gloria B. ; Hege, Kristen ; Riley, James L.
Frontiers in Immunology.  10 (2019)  - p. , 2019
Link: https://doi.org/10.3389/..
 
?
13

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (..:

Wolin, Edward ; Mita, Alain ; Mahipal, Amit...
PLOS ONE.  14 (2019)  9 - p. e0221994 , 2019
Link: https://doi.org/10.1371/..
 
?
14

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-..:

Munster, Pamela ; Mita, Monica ; Mahipal, Amit...
Cancer Management and Research.  11 (2019)  - p. 10463-10476 , 2019
Link: https://doi.org/10.2147/..
 
?
15

A phase I dose‐escalation study to assess safety, tolerabil..:

Bendell, Johanna C. ; Kelley, Robin K. ; Shih, Kent C....
Cancer.  121 (2015)  19 - p. 3481-3490 , 2015
Link: https://doi.org/10.1002/..
 
1-15